{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:47:46Z","timestamp":1768625266035,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,5,23]],"date-time":"2011-05-23T00:00:00Z","timestamp":1306108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients with rheumatic diseases including rheumatoid arthritis (RA) are at increased risk for infections related to both the disease and its treatments. These include uncommonly reported infections due to histoplasmosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Medical record review of all patients with a diagnosis of RA who developed new histoplasmosis infection in an endemic region between Jan 1, 1998 and Jan 30, 2009 and who were seen at Mayo Clinic in Rochester, Minnesota was performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Histoplasmosis was diagnosed in 26 patients. Most patients were on combination therapies; 15 were on anti-tumor necrosis factor (anti-TNF) agents, 15 on corticosteroids and 16 on methotrexate. Most received more than 6 months of itraconazole and\/or amphotericin treatment. Two patients died of causes unrelated to histoplasmosis. Anti-TNF treatment was restarted in 4\/15 patients, with recurrence of histoplasmosis in one.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In this largest single center series of patients with RA and histoplasmosis in the era of immunomodulatory therapy, we found that most patients had longstanding disease and were on multiple immunomodulatory agents. Most cases were pulmonary; typical signs and symptoms of disease were frequently lacking.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2334-11-145","type":"journal-article","created":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T06:43:36Z","timestamp":1306219416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009"],"prefix":"10.1186","volume":"11","author":[{"given":"Timothy C","family":"Olson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Bongartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia S","family":"Crowson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn D","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Orenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric L","family":"Matteson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,23]]},"reference":[{"issue":"5","key":"1515_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/00005792-198309000-00001","volume":"62","author":"B Sathapatayavongs","year":"1983","unstructured":"Sathapatayavongs B, Batteiger BE, Wheat J, Slama TG, Wass JL: Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore). 1983, 62 (5): 263-70.","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 3","key":"1515_CR2","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1086\/429999","volume":"41","author":"GS Deepe Jr","year":"2005","unstructured":"Deepe GS: Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis. 2005, 41 (Suppl 3): S204-7.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1515_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1128\/CMR.00027-06","volume":"20","author":"CA Kauffman","year":"2007","unstructured":"Kauffman CA: Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007, 20 (1): 115-32. 10.1128\/CMR.00027-06.","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"1515_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004, 38 (9): 1261-5. 10.1086\/383317.","journal-title":"Clin Infect Dis"},{"key":"1515_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criterial for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-24. 10.1002\/art.1780310302.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1515_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1056\/NEJM198601093140205","volume":"314","author":"LJ Wheat","year":"1986","unstructured":"Wheat LJ, Kohler RB, Tewari RP: Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med. 1986, 314 (2): 83-8. 10.1056\/NEJM198601093140205.","journal-title":"N Engl J Med"},{"issue":"1","key":"1515_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1086\/648724","volume":"50","author":"CA Hage","year":"2010","unstructured":"Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat JL: Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010, 50 (1): 85-92. 10.1086\/648724.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1515_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","volume":"83","author":"S Tsiodras","year":"2008","unstructured":"Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP: Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008, 83 (2): 181-94. 10.4065\/83.2.181.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"1515_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/md.0b013e3180679130","volume":"86","author":"MA Assi","year":"2007","unstructured":"Assi MA, Sandid MS, Baddour LM, Roberts GD, Walker RC: Systemic histoplasmosis: a 15-year retrospective institutional review of 111 patients. Medicine (Baltimore). 2007, 86 (3): 162-9. 10.1097\/md.0b013e3180679130.","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"1515_CR10","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","volume":"167","author":"KL Wood","year":"2003","unstructured":"Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, Wheat LJ, Twigg HL: Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med. 2003, 167 (9): 1279-82. 10.1164\/rccm.200206-563OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"1515_CR11","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006, 295 (19): 2275-85. 10.1001\/jama.295.19.2275.","journal-title":"JAMA"},{"issue":"9","key":"1515_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1592\/phco.2005.25.9.1181","volume":"25","author":"DJ Rychly","year":"2005","unstructured":"Rychly DJ, DiPiro JT: Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy. 2005, 25 (9): 1181-92. 10.1592\/phco.2005.25.9.1181.","journal-title":"Pharmacotherapy"},{"issue":"10","key":"1515_CR13","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1002\/art.10583","volume":"46","author":"JH Lee","year":"2002","unstructured":"Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN, Braun MM: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002, 46 (10): 2565-70. 10.1002\/art.10583.","journal-title":"Arthritis Rheum"},{"key":"1515_CR14","volume-title":"FDA ALERT","author":"FDA","year":"2008","unstructured":"FDA: Information for Healthcare Professionals: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). FDA ALERT. 2008, [http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124185.htm]"},{"issue":"7","key":"1515_CR15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.rmed.2005.09.020","volume":"100","author":"VV Jain","year":"2006","unstructured":"Jain VV, Evans T, Peterson MW: Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med. 2006, 100 (7): 1291-3. 10.1016\/j.rmed.2005.09.020.","journal-title":"Respir Med"},{"issue":"3","key":"1515_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1034\/j.1399-3062.2002.01016.x","volume":"4","author":"GM Vail","year":"2002","unstructured":"Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M: Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis. 2002, 4 (3): 148-51. 10.1034\/j.1399-3062.2002.01016.x.","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"1515_CR17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1086\/521259","volume":"45","author":"LJ Wheat","year":"2007","unstructured":"Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA, Infectious Diseases Society of America: Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007, 45 (7): 807-25. 10.1086\/521259.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1515_CR18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1086\/313752","volume":"30","author":"J Wheat","year":"2000","unstructured":"Wheat J, Sarosi G, McKinsey D, Hamill R, Bradsher R, Johnson P, Loyd J, Kauffman C: Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis. 2000, 30 (4): 688-95. 10.1086\/313752.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1515_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/00042560-199710010-00005","volume":"16","author":"FM Hecht","year":"1997","unstructured":"Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA, Powderly W: Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol. 1997, 16 (2): 100-7. 10.1097\/00042560-199710010-00005.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-11-145\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T14:51:48Z","timestamp":1630507908000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-11-145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,23]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-11-145","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,23]]},"assertion":[{"value":"21 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"145"}}